SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akcea Therapeutics, Inc. (AKCA)

NEW YORK, May 10, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akcea Therapeutics, Inc. ("Akcea" or the "Company")  (NASDAQ: AKCA). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/akca.  

The investigation concerns whether Akcea and certain of its officers and/or directors have violated federal securities laws.

On May 8, 2018, the U.S. Food and Drug Administration ("FDA") published briefing documents in advance of a May 10, 2018 advisory panel meeting regarding Akcea's volanesorsen product.  In the briefing documents, the FDA noted that significant portions of patients treated with volanesorsen had experienced steep reductions in their blood platelet counts.  On this news, Akcea's share price fell $2.87, or 13.24%, to close at $18.80.

If you are aware of any facts relating to this investigation, or purchased Akcea shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/akca. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

https://www.bgandg.com/